BMS-817399

TargetMol
Product Code: TAR-T26861
Supplier: TargetMol
CodeSizePrice
TAR-T26861-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-5mg5mg£430.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-1mL1 mL * 10 mM (in DMSO)£486.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-100mg100mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26861-500mg500mg£3,115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
BMS-817399 is a potent CCR1 antagonist with oral activity.
CAS:
1202400-18-7
Formula:
C23H36ClN3O4
Molecular Weight:
454.01
Pathway:
Microbiology/Virology|Immunology/Inflammation
Purity:
0.98
SMILES:
CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1
Target:
CCR

References

1. Chen H, Pui Y, Liu C, Chen Z, Su CC, Hageman M, Hussain M, Haskell R, Stefanski K, Foster K, Gudmundsson O, Qian F. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance. J Pharm Sci. 2018 Jan;107(1):317-326. doi: 10.1016/j.xphs.2017.10.028. Epub 2017 Oct 26. PubMed PMID: 29107047. 2. Khan JA, Camac DM, Low S, Tebben AJ, Wensel DL, Wright MC, Su J, Jenny V, Gupta RD, Ruzanov M, Russo KA, Bell A, An Y, Bryson JW, Gao M, Gambhire P, Baldwin ET, Gardner D, Cavallaro CL, Duncia JV, Hynes J Jr. Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. J Mol Biol. 2015 Feb 27;427(4):924-42. doi: 10.1016/j.jmb.2014.12.022. Epub 2015 Jan 8. PubMed PMID: 25579995. 3. Santella JB 3rd, Gardner DS, Duncia JV, Wu H, Dhar M, Cavallaro C, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno SW, Cvijic ME, Grafstrom RR, Liu R, Patel SR, Watson AJ, Yang G, Rose AV, Vickery RD, Caceres-Cortes J, Caporuscio C, Camac DM, Khan JA, An Y, Foster WR, Davies P, Hynes J Jr. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64. doi: 10.1021/jm5003167. Epub 2014 Sep 3. PubMed PMID: 25101488.